CAPS

Business Context and Reporting Period

Company: OrthoLogic Corp. (Note: Request metadata listed "Capstone Holding Corp.", but the filing text identifies the registrant as OrthoLogic Corp.)
Reporting Period: Quarterly period ended September 30, 2005.
Status: Development Stage Company.
Business Overview: OrthoLogic is a biotechnology company focused on the development and commercialization of Chrysalin (TP508), a synthetic peptide for tissue repair. The company has no revenue-generating operations, having sold its former bone device business in 2003. Current efforts are concentrated on clinical trials for fracture repair, diabetic ulcer healing, and cartilage defect repair.

Key Financial Metrics

Note: Q3 2004 and 9-month 2004 figures include a one-time $25.8 million charge for In-process R&D related to the acquisition of Chrysalis Biotechnology, Inc. (CBI).

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss for Q3 2005 decreased significantly to $7.6 million from $29.4 million in Q3 2004. This improvement is primarily due to the absence of the $25.8 million non-cash in-process R&D charge recorded in 2004 upon the CBI acquisition.
• Increased R&D Spend: Operating R&D expenses increased 51% in Q3 2005 ($7.3 million) compared to Q3 2004 ($4.8 million), driven by patient enrollment costs for Phase 2b and Phase 3 fracture repair trials.
• Cash Position: Cash and cash equivalents decreased by $8.6 million during the nine months ended September 30, 2005, primarily due to operating cash outflows of $19.5 million, partially offset by net investment maturities.
• Discontinued Operations: The company reported no income from discontinued operations in 2005, whereas Q3 2004 included a $1.7 million gain from the sale of the bone device business.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2005 Expenditure Forecast: Management expects total 2005 cash expenditures to be approximately $28.0 million. This includes R&D expenses rising to ~$27 million from $17.1 million in 2004.
• Escrow Receipt: The company anticipates receiving $7.0 million in cash from an indemnity escrow related to the 2003 sale of its bone device business in November 2005, which would reduce net cash expenditures to ~$21.0 million.
• Capital Needs: The company withdrew its Form S-3 registration statement in November 2005. Future funding for accelerated development will likely require equity/debt sales, joint ventures, or licensing agreements.
• Clinical Milestones: Enrollment for the pivotal Phase 3 fracture repair trial (503 patients) was completed in May 2005. Initial efficacy results are expected in the first half of 2006.

Risks and Contingencies

• Litigation: The company is appealing a $229,000 personal property tax assessment by Maricopa County, Arizona, believing the tax was applied incorrectly to leased property.
• Development Risk: All product candidates rely on the Chrysalin peptide. Negative safety or efficacy results in one indication could impact the entire platform.
• Regulatory Risk: No products are approved for sale. Commercialization depends on FDA approval, which is uncertain and costly.
• Liquidity: As a development-stage company with no revenue, the company relies on cash reserves and future financing to fund operations.

Investor Verification Checklist

• Cash Runway: Verify if the projected $28 million 2005 burn rate aligns with current cash reserves ($83.5 million total investments) and the timing of the $7 million escrow release.
• Clinical Trial Data: Monitor the release of Phase 3 fracture repair efficacy data expected in H1 2006, as this is the primary catalyst for future valuation.
• Capital Raising: Assess the company's ability to secure additional funding given the withdrawal of the Form S-3 registration statement.
• Intellectual Property: Review the status of the Patent Assignment Agreement with the University of Texas and the associated royalty increase to 3.0%.
• Legal Exposure: Track the resolution of the Maricopa County tax appeal and any potential impact on operating expenses.